Exelixis Inc
Latest Exelixis Inc News and Updates

The High Hope of Exelixis’s Cabometyx Label Expansion
Exelixis (EXEL) plans to explore Cabometyx in combination with immune checkpoint inhibitors such as atezolizumab, ipilimumab, and nivolumab.

What Amgen’s Analysts Recommend in August 2017
Of the 24 analysts covering Amgen, four have recommended a “strong buy” for the stock, while six have recommended a “buy.”

Exelixis Stock Rises on Revenue Beat
Yesterday, Exelixis (EXEL) reported its second-quarter results after markets closed. Subsequently, its stock rose 0.99% and closed at $21.48.

Exelixis Stock Is Up despite Disappointing Clinical Trial Results
While Exelixis was down 5.9% in after-hours trading after the announcement of disappointing clinical trial results, the stock recovered the losses and closed at $21.14 yesterday, 0.81% higher than its previous close. Based on this price performance, it seems that shareholders had already priced in the trial’s failure.

Sarepta Therapeutics Stock Rose 96% in 2018
On January 4, Sarepta Therapeutics (SRPT) stock closed at $115.43, which represents ~8.21% growth from its prior close.

Why Clovis Oncology Stock Rose 48% in November
On December 3, Clovis Oncology stock closed at $19.08, which represents ~10.87% growth from its close of $17.21 on November 30.

Why Exelixis Stock Soared 46% in November
Exelixis stock has experienced solid growth over the last month after it hit its 52-week low of $13.42 on October 29.

Lenvima Is Expected to Boost Merck’s Oncology Portfolio in 2018
Lenvima is expected to enable Merck to compete effectively with other oncology players such as Exelixis (EXEL) and Pfizer (PFE).

How United Therapeutics Performed in 1Q18
In 1Q18, United Therapeutics (UTHR) generated revenues of $389.2 million compared to $370.5 million in 1Q17.

Cabometyx Could Be Exelixis’s Long-Term Growth Driver
In March 2018, the FDA accepted Exelixis’s (EXEL) supplemental New Drug Application (or sNDA) for Cabometyx.

Pfizer’s Sutent Generated Higher Revenues in 4Q17
In the US and international markets in 4Q17, Sutent generated revenues of $96 million and $180 million, respectively.

Inside Exelixis’s Label Expansion Collaborations for Cabozantinib
As a part of the broader lifecycle management for Cabometyx, Exelixis is exploring the drug in combination with other immune checkpoint inhibitors.

Behind Exelixis’s Cabometyx Strategy for 2018
Exelixis (EXEL) expects the FDA’s approval for Cabometyx for first-line RCC (renal cell carcinoma) to be a major revenue driver.

Reading the Expectations for Exelixis’s Net Profit Margin in 2017
In 3Q17, Exelixis (EXEL) witnessed the rapid adoption of Cabometyx, mainly driven by the company’s promotional efforts focused on community oncologists.

How Is Cabometyx and Cometriq Positioned after 1H17?
In 2Q17, Exelixis’s (EXEL) Cabometyx generated revenues of ~$80.9 million compared to ~$17.6 million in 2Q16.

An Update on Novartis’s Sandostatin, Afinitor, and Exjade
In 1H17, Novartis’s (NVS) Sandostatin generated revenues of around $789 million, which reflected a ~4% decline on a year-over-year (or YoY) basis.

Bristol-Myers Squibb’s 2Q17 Earnings: Opdivo
Bristol-Myers Squibb’s (BMY) blockbuster drug Opdivo reported revenue of $1.2 billion in 2Q17, a 42% rise compared to $840 million in 2Q16.

Inside Exelixis’s Robust Growth Strategy for Cabometyx
Exelixis is now developing a strong sales team to support the commercial launch of Cabometyx for indications like first-line RCC and second-line HCC.

Exelixis’s Tough Competition in Renal Cell Carcinoma
After the launch of Cabometyx in the US in 2Q16, Exelixis has focused its attention on promoting it to thought leaders and clinicians who have treated many RCC patients.

Behind Exelixis’s Successful Commercial Launch of Cabometyx in 2016
Launched in the US in 2Q16, Exelixis’s (EXEL) Cabometyx managed to fetch revenues of $31.2 million and $44.7 million in 3Q16 and 4Q16, respectively.